| Richard A Sater, MD, PHD | |
|
912 3rd St Ste 101, Greensboro, NC 27405 | |
| (336) 273-2511 | |
| (336) 370-0287 |
| Full Name | Richard A Sater |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 33 Years |
| Location | 912 3rd St Ste 101, Greensboro, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174543805 | NPI | - | NPPES |
| 1173F | Other | NC | BCBSNC |
| 1174543805 | Medicaid | NC |
| Facility Name | Location | Facility Type |
|---|---|---|
| Moses H. Cone Memorial Hospital, The | Greensboro, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Moses Cone Affiliated Physicians, Inc. | 3779635396 | 72 |
News Archive
KYTHERA Biopharmaceuticals, Inc., a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, presented results from a long-term follow up study assessing persistence of efficacy and post-treatment safety of ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental fat.
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today that the United States Patent & Trademark Office (USPTO) and the European Patent Office (EPO) have issued key patents covering elements of Tekmira's leading lipid nanoparticle (LNP) technology, which is used to deliver nucleic acid therapeutics, including small interfering RNA (siRNA).
Medicinal Genomics, a private company headquartered in Marblehead, Mass., USA and the Netherlands, announced today that it has sequenced the entire genomes of Cannabis sativa and Cannabis indica, representing two strains of the therapeutic plant.
Array BioPharma Inc. announced today that a $10 million clinical research milestone was achieved in its collaboration with Celgene Corporation. Celgene and Array entered into this research collaboration in September 2007. Array anticipates initiating a Phase 1 dose escalation trial in cancer patients with ARRY-382, a small molecule cFMS inhibitor, during the first quarter of 2011.
A report by federal health care inspectors in November said the U.S. nursing home industry overbills Medicare $1.5 billion a year for treatments patients don't need or never receive.
› Verified 1 days ago
| Entity Name | Wake Forest Health Network Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477785756 PECOS PAC ID: 4183538895 Enrollment ID: O20031117000868 |
News Archive
KYTHERA Biopharmaceuticals, Inc., a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, presented results from a long-term follow up study assessing persistence of efficacy and post-treatment safety of ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental fat.
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today that the United States Patent & Trademark Office (USPTO) and the European Patent Office (EPO) have issued key patents covering elements of Tekmira's leading lipid nanoparticle (LNP) technology, which is used to deliver nucleic acid therapeutics, including small interfering RNA (siRNA).
Medicinal Genomics, a private company headquartered in Marblehead, Mass., USA and the Netherlands, announced today that it has sequenced the entire genomes of Cannabis sativa and Cannabis indica, representing two strains of the therapeutic plant.
Array BioPharma Inc. announced today that a $10 million clinical research milestone was achieved in its collaboration with Celgene Corporation. Celgene and Array entered into this research collaboration in September 2007. Array anticipates initiating a Phase 1 dose escalation trial in cancer patients with ARRY-382, a small molecule cFMS inhibitor, during the first quarter of 2011.
A report by federal health care inspectors in November said the U.S. nursing home industry overbills Medicare $1.5 billion a year for treatments patients don't need or never receive.
› Verified 1 days ago
| Entity Name | Moses Cone Affiliated Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346474103 PECOS PAC ID: 3779635396 Enrollment ID: O20090713000512 |
News Archive
KYTHERA Biopharmaceuticals, Inc., a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, presented results from a long-term follow up study assessing persistence of efficacy and post-treatment safety of ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental fat.
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today that the United States Patent & Trademark Office (USPTO) and the European Patent Office (EPO) have issued key patents covering elements of Tekmira's leading lipid nanoparticle (LNP) technology, which is used to deliver nucleic acid therapeutics, including small interfering RNA (siRNA).
Medicinal Genomics, a private company headquartered in Marblehead, Mass., USA and the Netherlands, announced today that it has sequenced the entire genomes of Cannabis sativa and Cannabis indica, representing two strains of the therapeutic plant.
Array BioPharma Inc. announced today that a $10 million clinical research milestone was achieved in its collaboration with Celgene Corporation. Celgene and Array entered into this research collaboration in September 2007. Array anticipates initiating a Phase 1 dose escalation trial in cancer patients with ARRY-382, a small molecule cFMS inhibitor, during the first quarter of 2011.
A report by federal health care inspectors in November said the U.S. nursing home industry overbills Medicare $1.5 billion a year for treatments patients don't need or never receive.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard A Sater, MD, PHD 912 3rd St Ste 101, Greensboro, NC 27405-6967 Ph: (336) 273-2511 | Richard A Sater, MD, PHD 912 3rd St Ste 101, Greensboro, NC 27405 Ph: (336) 273-2511 |
News Archive
KYTHERA Biopharmaceuticals, Inc., a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, presented results from a long-term follow up study assessing persistence of efficacy and post-treatment safety of ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental fat.
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today that the United States Patent & Trademark Office (USPTO) and the European Patent Office (EPO) have issued key patents covering elements of Tekmira's leading lipid nanoparticle (LNP) technology, which is used to deliver nucleic acid therapeutics, including small interfering RNA (siRNA).
Medicinal Genomics, a private company headquartered in Marblehead, Mass., USA and the Netherlands, announced today that it has sequenced the entire genomes of Cannabis sativa and Cannabis indica, representing two strains of the therapeutic plant.
Array BioPharma Inc. announced today that a $10 million clinical research milestone was achieved in its collaboration with Celgene Corporation. Celgene and Array entered into this research collaboration in September 2007. Array anticipates initiating a Phase 1 dose escalation trial in cancer patients with ARRY-382, a small molecule cFMS inhibitor, during the first quarter of 2011.
A report by federal health care inspectors in November said the U.S. nursing home industry overbills Medicare $1.5 billion a year for treatments patients don't need or never receive.
› Verified 1 days ago
Dr. Kim Gloria Hoover, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 510 N Elam Ave Ste 301, Greensboro, NC 27403 Phone: 336-832-9800 Fax: 336-832-1369 | |
Dr. Gerald Dale Taylor, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 201 N Eugene St, Greensboro, NC 27401 Phone: 336-641-3630 | |
Eliot Julian Lewit, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2721 Horse Pen Creek Rd, Ste 104, Greensboro, NC 27410 Phone: 336-268-2530 Fax: 336-268-2531 | |
Janardhana Rao Jonnalagadda, M.D. Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 2016 New Garden Rd, Suite C, Greensboro, NC 27410 Phone: 336-541-8111 Fax: 855-427-6593 | |
Dr. Michael Leroy Reynolds, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 912 Third Street, Suite 101, Greensboro, NC 27405 Phone: 336-273-2511 Fax: 336-370-0287 | |
Dr. Keertan Reddy, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 603 Dolley Madison Rd Ste 100, Greensboro, NC 27410 Phone: 216-545-8229 Fax: 217-545-2275 | |
Dr. Kumbaiah N Murthy, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 201 N Eugene St, Greensboro, NC 27401 Phone: 336-676-6840 Fax: 336-676-6490 |